±â¼úÀÌÀü
±â¼ú³»¿ª / ±¸ºÐ / »ê¾÷ü¸í
[2019] RNA silencing pathway¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú¿¡ ´ëÇÑ Ç×ü(LF-MA0209, LF-MA0244) 2°Ç¿¡ ´ëÇÑ Á¦Á¶ ±â¼ú
Know- how °ü·Ã ±â¼úÀÌÀü, ¿µÀÎÇÁ·±Æ¼¾î¢ß
[2019] 30mL of whole serum polyclonal antibody anti-LSD1 phospho-Serine 112(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2019] 1) ½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ À¯Àüü ±³Á¤ ½Ä¹°Ã¼¸¦ °íÈ¿À²·Î Á¦Á¶ÇÏ´Â ¹æ¹ý(10-1829885)
2) ½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ ½Ä¹°Ã¼¸¦ Á¦Á¶ÇÏ´Â ¹æ¹ý(10-2016-0129377)
À§ µÎ ƯÇã ¹× À̸¦ ±âÃÊ·Î ÇÏ´Â ¿ì¼±±Ç ÁÖÀå ÇØ¿ÜÃâ¿ø 20°Ç
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ßÁöÇ÷¯½º»ý¸í°úÇÐ
[2019] »ýü³» ´Ü¹éÁú »óÈ£ÀÛ¿ë ºÐ¼®À» À§ÇÑ È²»öÇü±¤´Ü¹éÁú N-¸»´Ü ÀýÆí ºÎÂø È¿¸ð ±ÕÁÖ ¶óÀ̺귯¸®(10-2009-0048746)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß¹ÙÀÌ¿À´Ï¾Æ
[2019] 1) ½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ À¯Àüü ±³Á¤ ½Ä¹°Ã¼¸¦ °íÈ¿À²·Î Á¦Á¶ÇÏ´Â ¹æ¹ý(10-1829885)
2) ½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ ½Ä¹°Ã¼¸¦ Á¦Á¶ÇÏ´Â ¹æ¹ý(10-2016-0129377)
À§ µÎ ƯÇã ¹× À̸¦ ±âÃÊ·Î ÇÏ´Â ¿ì¼±±Ç ÁÖÀå ÇØ¿ÜÃâ¿ø 20°Ç
ƯÇã °ü·Ã ±â¼úÀÌÀü, (ÁÖ)ÁöÇ÷¯½º»ý¸í°úÇÐ
[2018] RNA silencing pathway¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú¿¡ ´ëÇÑ Ç×ü(LF-MA0209, LF-MA0244) 2°Ç¿¡ ´ëÇÑ Á¦Á¶ ±â¼ú
Know- how °ü·Ã ±â¼úÀÌÀü, ¿µÀÎÇÁ·±Æ¼¾î¢ß
[2018] 5ml of polyclonal antibody to Srg3
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2018] 30mL of whole serum polyclonal antibody anti-LSD1 phospho-Serine 112(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2018] a) Anti-Lin28A, clone 2J3
b) Anti-Lin28A, clone 35L33G
c) Anti-Lin28B, clone 17A2
d) Anti-Lin28B, clone 15G3(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2018] »ýü³» ´Ü¹éÁú »óÈ£ÀÛ¿ë ºÐ¼®À» À§ÇÑ È²»öÇü±¤´Ü¹éÁú N-¸»´Ü ÀýÆí ºÎÂø È¿¸ð ±ÕÁÖ ¶óÀ̺귯¸®(10-2009-0048746)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß¹ÙÀÌ¿À´Ï¾Æ
[2017] CXCR4-GPCR heterodimer °ËÁõ ±â¼ú(º°Ã· »ó¼¼ ¸í½Ã)_(³ëÇÏ¿ì)
Know- how °ü·Ã ±â¼úÀÌÀü, ¢ßÁöÇǾ¾¾Ë
[2017] RNA silencing pathway¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú¿¡ ´ëÇÑ Ç×ü(LF-MA0209, LF-MA0244) 2°Ç¿¡ ´ëÇÑ Á¦Á¶ ±â¼ú
Know- how °ü·Ã ±â¼úÀÌÀü, ¿µÀÎÇÁ·±Æ¼¾î¢ß
[2017] 30mL of whole serum polyclonal antibody anti-LSD1 phospho-Serine 112(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2017] 5ml of polyclonal antibody to Srg3
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2017] a) Anti-Lin28A, clone 2J3
b) Anti-Lin28A, clone 35L33G
c) Anti-Lin28B, clone 17A2
d) Anti-Lin28B, clone 15G3(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2017] ½Ä¹°ÀÇ »ýÀåÀ» ÃËÁøÇÏ´Â gul1/sur2-7 À¯ÀüÀÚ ¹× »ó±â À¯ÀüÀÚ°¡ µµÀÔµÈ ÇüÁúÀüȯ ½Ä¹°Ã¼(´ëÇѹα¹Æ¯Çã Á¦10-1759089È£)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ßÁöÇ÷¯½º»ý¸í°úÇÐ
[2017] 1.½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ ½Ä¹°Ã¼¸¦ Á¦Á¶ÇÏ´Â ¹æ¹ý (METHOD FOR PRODUCING WHOLE PLANTS FROM PROTOPLASTS)(KR10-2016-0129377PCT/KR2016/011217)
2.½Ä¹° ¿øÇüÁúü·ÎºÎÅÍ À¯Àüü ±³Á¤ ½Ä¹°Ã¼¸¦ °íÈ¿À²·Î Á¦Á¶ÇÏ´Â ¹æ¹ý (A METHOD FOR PREPARING A GENOME-EDITED PLANT FROM PROTOPLASTS)(KR10-2016-0129356PCT/KR2016/011216)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ßÁöÇ÷¯½º»ý¸í°úÇÐ
[2017] »ýü³» ´Ü¹éÁú »óÈ£ÀÛ¿ë ºÐ¼®À» À§ÇÑ È²»öÇü±¤´Ü¹éÁú N-¸»´Ü ÀýÆí ºÎÂø È¿¸ð ±ÕÁÖ ¶óÀ̺귯¸®(10-2009-0048746)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß¹ÙÀÌ¿À´Ï¾Æ
[2016] RNA silencing pathway¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú¿¡ ´ëÇÑ Ç×ü(LF-MA0209, LF-MA0244) 2°Ç¿¡ ´ëÇÑ Á¦Á¶ ±â¼ú
Know- how °ü·Ã ±â¼úÀÌÀü, ¿µÀÎÇÁ·±Æ¼¾î¢ß
[2016] 30mL of whole serum polyclonal antibody anti-LSD1 phospho-Serine 112(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2016] a) Anti-Lin28A, clone 2J3
b) Anti-Lin28A, clone 35L33G
c) Anti-Lin28B, clone 17A2
d) Anti-Lin28B, clone 15G3(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD MILLIPORE
[2016] ÅðÇ༺ ³úÁúȯ Ä¡·á¿ë ¡°ALK ÀúÇØÁ¦¡± ½Å¾àÈĺ¸¹°Áú ¹ß±¼À» ¸ñÇ¥·Î °øµ¿ ¿¬±¸¸¦ ¼öÇàÇÑ °á°ú·Î »êÃâµÇ´Â ÀÏüÀÇ Áö½ÄÀç»ê±Ç
(ƯÇã¸í : Ÿ¿ì ´Ü¹éÁú ¸Å°³ ½Å°æ ÅðÇ༺ Áúȯ Ä¡·áÁ¦(METHOD FOR TREATING TAU PROTEIN-MEDIATED DEGENERATIVE NEURONAL DISEASE))
ƯÇã °ü·Ã ±â¼úÀÌÀü, (ÁÖ)·¹°íÄ͹ÙÀÌ¿À»çÀ̾ð½º
[2016] »ýü³» ´Ü¹éÁú »óÈ£ÀÛ¿ë ºÐ¼®À» À§ÇÑ È²»öÇü±¤´Ü¹éÁú N-¸»´Ü ÀýÆí ºÎÂø È¿¸ð ±ÕÁÖ ¶óÀ̺귯¸®(10-2009-0048746)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß¹ÙÀÌ¿À´Ï¾Æ
[2015] Wnt ½ÅÈ£Àü´Þ°è ´Ü¹éÁú¿¡ ´ëÇÑ Àΰ£È­Ç×ü¸¦ ÀÌ¿ëÇÑ Ç×¾ÏÁ¦ ¹× Áø´Ü½Ã¾à °³¹ß ±â¼ú(³ëÇÏ¿ì)
Know- how °ü·Ã ±â¼úÀÌÀü, ½´³Ú»ý¸í°úÇÐ
[2015] VDAC ´Ü¹éÁúÀÇ È°¼ºÀ» Ÿ±êÀ¸·Î ÇÏ´Â »õ·Î¿î ÆÄŲ½¼º´ Ä¡·áÁ¦ °³¹ß ±â¼ú(³ëÇÏ¿ì)
Know- how °ü·Ã ±â¼úÀÌÀü, ¢ß¿¡ÀÌÇÁ·ÎÁ¨
[2015] RNA silencing pathway¿¡ °ü¿©ÇÏ´Â ´Ü¹éÁú¿¡ ´ëÇÑ Ç×ü(LF-MA0209, LF-MA0244) 2°Ç¿¡ ´ëÇÑ Á¦Á¶ ±â¼ú
Know- how °ü·Ã ±â¼úÀÌÀü, ¿µÀÎÇÁ·±Æ¼¾î¢ß
[2015] 30mL of whole serum polyclonal antibody anti-LSD1 phospho-Serine 112(¹°ÁúÀÌÀü°è¾à)
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD Millipore Corporation
[2015] 5ml of polyclonal antibody to Srg3
ÁöÀû Àç»ê±Ç °ü·Ã ±â¼úÀÌÀü, EMD Millipore Corporation
[2015] ¹ÙÀÌ·¯½º º¤Å͸¦ ÀÌ¿ëÇÏ¿© ´Ü¹éÁúÀÇ »óÈ£ÀÛ¿ëÀ» ÃøÁ¤ÇÏ´Â ¹æ¹ý
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ßÁöÇǾ¾¾Ë
[2015] ÅðÇ༺ ³úÁúȯ Ä¡·á¿ë ¡°ALK ÀúÇØÁ¦¡± ½Å¾àÈĺ¸¹°Áú ¹ß±¼À» ¸ñÇ¥·Î °øµ¿ ¿¬±¸¸¦ ¼öÇàÇÑ °á°ú·Î »êÃâµÇ´Â ÀÏüÀÇ Áö½ÄÀç»ê±Ç
(ƯÇã¸í : Ÿ¿ì ´Ü¹éÁú ¸Å°³ ½Å°æ ÅðÇ༺ Áúȯ Ä¡·áÁ¦(METHOD FOR TREATING TAU PROTEIN-MEDIATED DEGENERATIVE NEURONAL DISEASE))
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß·¹°íÄÍ ¹ÙÀÌ¿À»çÀ̾ð½º
[2015] »ýü³» ´Ü¹éÁú »óÈ£ÀÛ¿ë ºÐ¼®À» À§ÇÑ È²»öÇü±¤´Ü¹éÁú N-¸»´Ü ÀýÆí ºÎÂø È¿¸ð ±ÕÁÖ ¶óÀ̺귯¸®(10-2009-0048746)
ƯÇã °ü·Ã ±â¼úÀÌÀü, ¢ß¹ÙÀÌ¿À´Ï¾Æ